title: [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
abstract: Regorafenib is recommended as a third-line treatment for unresectable gastrointestinal stromal tumors (GIST). It is usually administered in a repeating cycle of three-weeks on and one-week off. We describe a patient with an unresectable GIST in the pelvic cavity who complained of pelvic pain while taking the one-week break from regorafenib administration. Subsequently, we reduced the dosage to one level and regorafenib was continuously administered. As a result, the adverse events were improved and the antitumor effect against the GIST was retained. The continuous administration of reduced-dose regorafenib could be considered a viable dosage adjustment in specific situations.
authors.affiliation: Department of Gastroenterology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
authors.forename: Shinya
authors.initials: S
authors.lastname: Kajiura
authors.forename: Ayumu
authors.initials: A
authors.lastname: Hosokawa
authors.forename: Sohachi
authors.initials: S
authors.lastname: Nanjyo
authors.forename: Naokatsu
authors.initials: N
authors.lastname: Nakada
authors.forename: Takayuki
authors.initials: T
authors.lastname: Ando
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010671:Phenylurea Compounds / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D011758:Pyrroles / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000473:pathology*; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; C559147:regorafenib; D000068877:Imatinib Mesylate; D000077210:Sunitinib